Medical examination, treatment and follow-up of ovarian cancer in Norway;Utredning, behandling og etterkontroll av eggstokkreft i Norge

Tidsskrift for den Norske Laegeforening

Volumn 121, Issue 23, 2001, Pages 2696-2700

  Paulsen, T ^a   Kjaerheim K ^a  

^a Kreftregisteret   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; EPIRUBICIN; ETOPOSIDE; PACLITAXEL; TAMOXIFEN CITRATE; THIOTEPA; TOPOTECAN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CYTOLOGY; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; GOVERNMENT; GYNECOLOGICAL EXAMINATION; GYNECOLOGY; HOSPITAL DEPARTMENT; HOSPITAL SERVICE; HUMAN; MEDICAL EXAMINATION; NORWAY; OUTPATIENT DEPARTMENT; OVARY CANCER; PATIENT CARE; PATIENT REFERRAL; PLEURA EFFUSION; QUALITY CONTROL; QUESTIONNAIRE; TRANSVAGINAL ECHOGRAPHY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; NORWAY; OVARIAN NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; QUALITY ASSURANCE, HEALTH CARE; QUESTIONNAIRES;

EID: 0035975517     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Revised FIGO staging for gynaecological cancer
2. DNA-ploiditet ved epitelial ovarialkreft - En uavhengig prognostisk faktor
3. Rutinekontroller etter gynekologisk cancerbehandling
4. Early detection of familial ovarian cancer
5. Prospectively detected cancer in familial breast/ovarian cancer screening
6. Epithelial ovarian cancer, infertility and induction of ovulation: Possible pathogenesis and updated concepts
7. MR imaging and CT of the female pelvis: Radiologic-pathologic correlation
8. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals
9. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses
10. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse
11. Lymfadenektomiens rolle ved gynekologiske canceroperasjouer
12. Epithelial ovarian carcinoma
13. Kontroverser ved kirurgisk behandling av avansert ovarialcancer
14. Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study
15. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer
16. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
17. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer
18. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study
19. Primary cytoreductive surgery for epithelial ovarian cancer
20. Cytoreduction in ovarian cancer: Achievability and results
21. The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: A prospective study
22. Primary surgical therapy of ovarian cancer: How much and when
23. Stage IV ovarian cancer: Impact of surgical debulking
24. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma
25. Management of ovarian cancer: Referral to a multidisciplinary team matters
26. The impact of specialist training for surgery in ovarian cancer
27. A critique of surgical cytoreduction in advanced ovarian cancer
28. Adjuvant treatment for early epithelial ovarian cancer: Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)
29. Tamoxifen in the treatment of recurrent ovarian carcinoma
30. Hormone replacement therapy after epithelial ovarian cancer treatment